Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation + Lenvatinib + Tislelizumab vs FOLFOX in Advanced ICC
NCT06860477Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, lenvatinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Fudan University. Started Mar 2025; status: recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06860477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860477.